Comparison · NCT02861014-sae
Ocrelizumab vs Ocrelizumab Safety Follow-up: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Ocrelizumab vs Ocrelizumab Safety Follow-up: serious adverse events. Trial comparisons, record NCT02861014-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02861014-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0721 | 0.0549 | 0.094 | wilson | |
| Risk in group 2 | 0.0938 | 0.0437 | 0.19 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0217 | -0.119 | 0.033 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.769 | 0.343 | 1.72 | log | |
| Odds ratio, group 1 over group 2 | 0.751 | 0.308 | 1.83 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Ocrelizumab than on Ocrelizumab Safety Follow-up | 46.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Ocrelizumab | Participants received Ocrelizumab as two 300 mg IV infusions on Days 1 and 15 followed by one 600 mg IV infusions administered at Weeks 24, 48, and 72. | 49 | 680 | EG000 |
| Group 2 | Ocrelizumab Safety Follow-up | Participants received Ocrelizumab as two 300 mg IV infusions on Days 1 and 15 followed by one 600 mg IV infusions administered at Weeks 24, 48, and 72. | 6 | 64 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From Baseline up to to 96 weeks after the end of the Treatment Period. Time frame includes the safety-follow-up period.
Source ClinicalTrials.gov
Trial
- Title
- A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
- NCT number
- NCT02861014
- Phases
- PHASE3
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Ocrelizumab
- Lead sponsor
- Hoffmann-La Roche
- Results first posted
- 2021-02-03
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02861014?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02861014-sae